# Prolacta Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prolacta-bioscience

- Industry: Biotechnology
- Headquarters: City of Industry, US
- Website: www.prolacta.com
- Total disclosed funding: $36M
- Latest round: Series D (Nov 3, 2011)
- Investors on record: 13

## About

Prolacta Bioscience Inc. develops and manufactures innovative human milk-based fortifiers aimed at improving health outcomes for vulnerable infants in neonatal intensive care units.Founded in 1999 and headquartered in City of Industry, US, Prolacta Bioscience specializes in human milk-based nutritional solutions. The company has not undergone any notable pivots or changes in operations. Prolacta has raised a total of USD 15.00 mn across 7 deals, with the latest round being a VENTURE DEBT of USD 35.00 mn on December 6, 2016, led by Essex Woodlands and including Aisling Capital and Health Evolution Partners as investors. The CEO of the company is Scott Elster.Prolacta Bioscience specializes in the development and manufacturing of human milk-based fortifiers specifically designed for neonatal intensive care units (NICUs). Their flagship product, Surgifort®, is the first and only 100% human milk-based fortifier approved by the US FDA for term infants with gastroschisis who have undergone corrective surgical procedures. The company’s products aim to enhance feeding tolerance and support adequate growth for preterm and critically ill infants while minimizing complications such as necrotizing enterocolitis (NEC). Prolacta’s products are clinically backed and widely adopted in hospitals across North America, Europe, and Australia.Prolacta Bioscience generates revenue through direct sales of its human milk-based fortifiers and nutritional products to hospitals and healthcare facilities. Their transaction structure typically involves B2B agreements, ensuring that hospitals procure products for their NICUs. The sales process is supported by clinician-to-clinician guidance and partnerships that enhance the implementation of optimal feeding protocols. Prolacta’s commitment to delivering high-quality products and providing education and support services to healthcare providers bolsters its competitive position in the neonatal nutrition market.Prolacta Bioscience aims to expand its product offerings and enhance its market presence. While specific upcoming products have not been detailed, the company is focusing on developing innovative nutritional solutions for infants. Plans for geographic expansion include targeting new markets beyond its current stronghold in North America, Europe, and Australia, with a strategic timeline aiming for increased presence in emerging markets by the end of 2025. The recent VENTURE DEBT funding of USD 35.00 mn will support these initiatives, allowing for investment in product development and market entry strategies.

## Funding rounds

- Series D, Nov 3, 2011, $15M — Health Evolution Partners
- Series C, May 23, 2007, $12M — Alta Partners, Arcturus Capital, Funk Ventures, Frontier Venture Capital, Mercury, Phillip Private Equity, Draper & Associates Inc, The Gideon Hixon Fund
- Series B, Oct 5, 2006, $5M — Arcturus Capital, Draper Richards Kaplan Foundation, Funk Ventures, Frontier Venture Capital, Mercury, The Gideon Hixon Fund, Draper
- Series B, Jun 15, 2005, $4M — Draper Fisher Jurvetson, Jupiter Partners, Draper Richards Kaplan Foundation, Draper & Associates Inc

## Investors

- Draper Fisher Jurvetson (https://capitalatlas.ai/funds/draper-fisher-jurvetson) — Series B
- Jupiter Partners (https://capitalatlas.ai/funds/jupiter-partners) — Series B
- Draper Richards Kaplan Foundation (https://capitalatlas.ai/funds/draper-richards-kaplan-foundation) — Series B
- Draper & Associates Inc — Series B, Series C
- Arcturus Capital (https://capitalatlas.ai/funds/arcturus-capital) — Series B, Series C
- Funk Ventures (https://capitalatlas.ai/funds/funk-ventures) — Series B, Series C
- Frontier Venture Capital (https://capitalatlas.ai/funds/frontier-venture-capital) — Series B, Series C
- Mercury (https://capitalatlas.ai/funds/mercury) — Series B, Series C
- The Gideon Hixon Fund (https://capitalatlas.ai/funds/the-gideon-hixon-fund) — Series B, Series C
- Draper (https://capitalatlas.ai/funds/draper) — Series B
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series C
- Phillip Private Equity (https://capitalatlas.ai/funds/phillip-private-equity) — Series C
- Health Evolution Partners (https://capitalatlas.ai/funds/health-evolution-partners) — Series D